The 21st Annual Scientific Meeting of the European Society of Hypertension (ESH), held in Milan on August 2nd, released the latest data on the TEAMSTA Diabetes Study: Angiotensin II Receptor Antagonist (ARB) Sardan and Calcium Channel Blocker (CCB) Amlodipine Single Tablet Compound TWYNSTA (containing telmisartan 80 mg and amlodipine 10 mg once daily) can be used for diabetic patients with hypertension To quickly and effectively depressurize. The results of this study confirm once again that TWYNSTA can provide more significant blood pressure benefits to hypertensive patients who are at higher risk of severe cardiovascular events, as compared to amlodipine monotherapy.

"High blood pressure is very common in patients with diabetes and those with a high risk of serious cardiovascular events such as stroke or heart attack." Arya, chairman of the Institute of Obesity Research and Management, Alberta University, Alberta, Canada, and author of the TEAMSTA Diabetes Study M. Dr. Sharma said. "The results of this study show that TWYNSTA is able to achieve higher rates of compliance for 24-hour blood pressure control in subjects. In addition, these patients often require multiple drug treatments due to comorbidities such as type 2 diabetes, and TWYNSTA can Reduce the patient's burden of medication."

TWYNSTA is a combination of two drugs that have the longest duration of efficacy in their respective drug classes.

The TEAMSTA Diabetes Study is an 8-week, double-blind, parallel-group study and is part of the telmisartan plus amlodipine III/IV clinical research program. A total of 706 patients with type 2 diabetes with grade 1 or 2 hypertension (defined as systolic blood pressure [SBP]> 150 mmHg) were included in this study. Subjects were randomized to receive TWYNSTA treatment (n=352) or amlodipine 10 mg treatment (n=354). The primary endpoint of the study was the change in mean systolic pressure from baseline.

The results of the study showed that compared with the amlodipine monotherapy group, the compound preparation treatment group had the following characteristics: at the 8th week of treatment, the mean systolic blood pressure decreased significantly (-29 mmHg vs. 22.9 mmHg; p<0.0001); In the first week, a significant decrease in mean systolic blood pressure was observed (-17.5 mmHg vs-12.6 mmHg; p<0.0001), and this difference was consistently maintained throughout the study; there was a consistently higher clinic blood pressure control compliance rate ( <140/90mmHg) and systolic control (<140mmHg) compliance (71.4% and 73.2% vs 53.8% and 56.8%); higher 24-hour blood pressure control compliance rate (assessed by ambulatory blood pressure monitoring, ie ABPM, contraction Pressure: -16.5mmHg vs 11.1mmHg; p = 0.0044), and stable, higher 24-hour blood pressure control compliance (<130/80mmHg; 52.9% vs 39.1%); good safety and tolerability, less occurrence Treatment-related adverse events and treatment discontinuation.

It is worth noting that more than 71% of hypertensive patients with diabetes treated with TWYNSTA (basal blood pressure 161/91 mmHg) achieved study-defined blood pressure control goals (<140/90 mmHg, amlodipine monotherapy The group was 54%) and more than 50% of patients achieved the 24-hour blood pressure control goals assessed by ABPM (<130/80 mmHg, 39% for amlodipine monotherapy). Similar results have also been observed in obese patients (body mass index, ie BMI ≥30 kg/m2) (obese patients are also the largest patient subgroup in the TEAMSTA Diabetes Study, accounting for approximately 57% of the total number of patients). Many studies have confirmed that monotherapy can only achieve blood pressure control goals in less than 40% of hypertensive patients. This figure is lower in patients with accompanying diseases such as obesity or diabetes.

These data from the “TEAMSTA Diabetes Study” reconfirmed the results from a previously conducted factorial-designed subgroup analysis study, which showed that in TWYNSTA-treated diabetic and obese patients, there were 87% and Eighty-one percent of patients achieved the study-defined blood pressure control goal of blood pressure <140/90 mmHg. The results of the TEAMSTA Diabetes Study further enriched the data from the previous study and showed that TWYNSTA can produce sustained antihypertensive effects in hypertensive patients of varying severity (mild to severe); in patients with severe hypertension The systolic pressure drop can be as high as 50mmHg. The data presented in this study shows the effectiveness of TWYNSTA in those patients who are at risk of additional cardiovascular events and who are generally more difficult to achieve blood pressure control goals. In hypertensive patients, TWYNSTA can achieve 80% of the peak blood pressure drop within two weeks after starting treatment, suggesting that the drug is rapid and effective.

The above findings further support previous research data on TWYNSTA, suggesting that this single-plate combination is a valuable treatment option for hypertensive patients, especially those with comorbid conditions such as diabetes or obesity.